Orexin loss in Huntington's disease. - Wikidata - wikimedia - TriplyDB

Orexin loss in Huntington's disease.

Orexin loss in Huntington's disease.

http://www.wikidata.org/entity/Q45295272

about

Chronic sleep disturbance and neural injury: links to neurodegenerative disease Neural and mesenchymal stem cells in animal models of Huntington's disease: past experiences and future challenges Mouse models of polyglutamine diseases: review and data table. Part I Functional Differences Between Direct and Indirect Striatal Output Pathways in Huntington's Disease Genetics and neuropathology of Huntington's disease Responses to environmental enrichment differ with sex and genotype in a transgenic mouse model of Huntington's disease Maintenance of basal levels of autophagy in Huntington's disease mouse models displaying metabolic dysfunction Effects of deletion of mutant huntingtin in steroidogenic factor 1 neurons on the psychiatric and metabolic phenotype in the BACHD mouse model of Huntington disease Sleep and circadian dysfunction in neurodegenerative disorders: insights from a mouse model of Huntington's disease Functional roles for the striatal-enriched transcription factor, Bcl11b, in the control of striatal gene expression and transcriptional dysregulation in Huntington's disease Huntingtin-associated protein 1 regulates exocytosis, vesicle docking, readily releasable pool size and fusion pore stability in mouse chromaffin cells Neuropeptide Y (NPY) in cerebrospinal fluid from patients with Huntington's Disease: increased NPY levels and differential degradation of the NPY1-30 fragment.Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis.Dysfunctions in circadian behavior and physiology in mouse models of Huntington's disease.Proliferative hypothalamic neurospheres express NPY, AGRP, POMC, CART and Orexin-A and differentiate to functional neurons.Neuroendocrine disturbances in Huntington's disease Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease.The tyrosine kinase receptor Tyro3 enhances lifespan and neuropeptide Y (Npy) neuron survival in the mouse anorexia (anx) mutation.Body composition in premanifest Huntington's disease reveals lower bone density compared to controls Microcirculation response to local cooling in patients with Huntington's disease.Sleep disorders, obesity, and aging: the role of orexin Animal models of Huntington's disease.Volumetric analysis of the hypothalamus in Huntington Disease using 3T MRI: the IMAGE-HD Study.Is Dysregulation of the HPA-Axis a Core Pathophysiology Mediating Co-Morbid Depression in Neurodegenerative Diseases?A 24-Hour Study of the Hypothalamo-Pituitary Axes in Huntington's Disease.A comparative analysis of the distribution of immunoreactive orexin A and B in the brains of nocturnal and diurnal rodents.The wake-promoting effects of hypocretin-1 are attenuated in old rats.Metabolic and behavioral effects of mutant huntingtin deletion in Sim1 neurons in the BACHD mouse model of Huntington's disease.Hypothalamic overexpression of mutant huntingtin causes dysregulation of brown adipose tissue.Environmental enrichment rescues female-specific hyperactivity of the hypothalamic-pituitary-adrenal axis in a model of Huntington's disease.Euglycemic agent-mediated hypothalamic transcriptomic manipulation in the N171-82Q model of Huntington disease is related to their physiological efficacy.Insights from studying human sleep disorders.Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies.Suprachiasmatic nucleus neuropeptide expression in patients with Huntington's Disease.Neuropeptides controlling energy balance: orexins and neuromedins.Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy The corticostriatal pathway in Huntington's disease.Multiple pathways contribute to the pathogenesis of Huntington disease.Protection by dietary restriction in the YAC128 mouse model of Huntington's disease: Relation to genes regulating histone acetylation and HTT.

P2860

Q26766524-E1F4E10B-289B-4EB0-AE01-727D9DBDE0DE Q26775932-B2D84EB1-0597-446F-8851-4A9D847D1D02 Q26853025-E6C7992B-2453-426C-8A27-1870049D0442 Q27015687-EF283A94-5772-4D31-A60E-60FA915EC17B Q27023050-A229F1B2-ADCB-4306-81F1-E2D57F0B0A89 Q27334872-119E19E9-6F42-4AAD-9EF9-9D2A6EEFDACC Q27341821-FD032D67-BEDC-4D4C-B741-CA40D6539B14 Q27346849-B397291C-F2CD-462E-95F4-E49EDD5174EF Q28383062-87AD7020-324C-4AA8-8C07-731FC12CF8DD Q28507781-CC98A97C-8703-4D3C-8858-DC085FEEF3D8 Q28511792-587B7C53-5686-4C22-833B-53EAD87B020B Q30315395-C8A7CEC9-5DE9-424F-A1EC-E23AAB971219 Q30497024-938E0DE2-307E-4EA0-997D-6DB55EAB8198 Q30623834-6A8E7824-A1DC-4FD8-BF37-B6A96B08894F Q31011157-717638D8-F583-4FD2-8DBD-E4516D0D94BE Q33421708-A2B135DD-A8A9-4723-A954-E33B7C94CF9F Q33517121-5CBB1836-2C9A-45C2-A8E9-9DAD86B1EB40 Q33746241-83DC9151-3B10-4750-999B-D09F96FD7A29 Q33838303-3D7AC06C-9274-4D8C-8B76-36F526BA7932 Q34052018-573CDC92-9C99-47EF-B973-81C39E92FB96 Q34451399-8D8EE326-0455-42D4-A244-DE9069506758 Q34665829-61D4E711-4174-477E-B24B-1434C5A18B9A Q35058349-9472B40C-A9BC-4CAA-AEF8-CDAD6D75C599 Q35158376-9B5D1B53-12D6-480F-8F58-E7027044471F Q35797126-9A8963BB-DE43-41CD-9AB1-3E17A252345D Q35878433-83EF3978-7F49-47AB-A4C2-64CB2CF8F657 Q36003547-50217738-AF89-4C13-80C3-2DC090AC512D Q36059260-0F6D0D4A-A52B-4408-B3DF-121E991EF75A Q36106687-5F3541F7-579D-4327-B648-821E5BB74C67 Q36136010-A3238CBA-F3BF-49D0-8CC5-A96D638C87C1 Q36234711-9A240B55-25D0-48BC-AC6E-213A8A79D9B2 Q36298341-5A9CA5F1-8798-4E30-8A93-583E789B2C30 Q36315067-5CC78920-517F-43C0-981D-947908BBB0BB Q36358871-F783249C-3A99-4818-9084-A29C8A3848EA Q36473222-FDD8B619-811B-40D8-A661-432C6E006DCC Q36531499-ABCE8CBF-239B-4054-9223-69D68AD7BDFF Q36608029-8FAF0140-22B3-4787-B3B7-4B9F2102EE75 Q36684263-68BF323D-A63E-47AD-A65D-B5BB3E7D0AD8 Q36686156-D362D7C7-16CE-404E-BA71-1604C86201ED Q36763900-B02F7806-342B-429F-BD41-974617E7BCCE

P2860

Orexin loss in Huntington's disease.

http://www.wikidata.org/entity/Q45295272

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Orexin loss in Huntington's disease.

@en

Orexin loss in Huntington's disease.

@nl

type

label

Orexin loss in Huntington's disease.

@en

Orexin loss in Huntington's disease.

@nl

prefLabel

Orexin loss in Huntington's disease.

@en

Orexin loss in Huntington's disease.

@nl

P1433

Q45295272-5BAB2753-BEFC-4B3A-8061-F977B731CA6F

P1476

Q45295272-25900D00-43AB-4DC7-912E-608BE487F99D

P2093

Q45295272-012E179A-7A03-411C-BA05-C2334202CDA9

Q45295272-01B24EEF-80F1-48E3-8CF1-07D91AF3FFF3

Q45295272-183ECCF5-4FB0-4EB9-8DBF-8E329A7A0AF6

Q45295272-33E858D0-4867-4477-B7C3-093967FE7A92

Q45295272-4EC8ED44-6E43-41BE-BFAA-065750A6E1B1

Q45295272-668695F8-1F1B-465D-B054-E26556BEDD05

Q45295272-97EDC11F-F328-4806-8CE6-62F3F78BF34F

Q45295272-D389C825-84F1-49FC-8257-AD0EFAEF343A

Q45295272-F37B2F57-1F0F-4D3E-A902-81717208DA63

P304

Q45295272-0C3489AD-1A29-45B1-9CB2-3D8BAE6889C0

P31

Q45295272-253F6387-9096-460B-932F-AB7830AA04E4

P356

Q45295272-ABC9F654-153E-4C39-B6BB-3F5CAF9C3959

P433

Q45295272-71C92384-FD88-425B-8C01-40360A87B816

P478

Q45295272-A69C1CA4-7331-47F5-ACEF-029C15A346ED

P50

Q45295272-1849F025-3D2A-49F0-9C0A-53FE94E6499A

Q45295272-56F47732-CE47-4D0D-8AA8-5F2B501D4A0B

Q45295272-5B53F405-5964-4EC1-BFEF-F3E65BACFE81

Q45295272-72A621C3-D621-4006-B802-02286BB697AA

Q45295272-A49108E1-09A5-41A7-85DA-0A21C13592F7

Q45295272-F9798EDE-A214-4BF4-98D6-E857E56DF019

P577

Q45295272-56B3387E-9CB7-40DF-958C-C64FF6AA3974

P5875

Q45295272-A70AD905-7E4A-4F3F-8896-419DA06F5727

P698

Q45295272-45790D80-4DB6-42CC-80FE-69BEF81AB8EB

P921

Q45295272-87929744-FB32-4E8D-9D6C-6983D74E34B5

P356

P1433

Human Molecular Genetics

P1476

Orexin loss in Huntington's disease

@en

P2093

Asa Petersén

http://www.w3.org/2001/XMLSchema#string

Frank Sundler

http://www.w3.org/2001/XMLSchema#string

Heikki Tanila

http://www.w3.org/2001/XMLSchema#string

Joana Gil

http://www.w3.org/2001/XMLSchema#string

Marion L C Maat-Schieman

http://www.w3.org/2001/XMLSchema#string

Natalija Popovic

http://www.w3.org/2001/XMLSchema#string

Nils Wierup

http://www.w3.org/2001/XMLSchema#string

Patrik Brundin

http://www.w3.org/2001/XMLSchema#string

Per Norlén

http://www.w3.org/2001/XMLSchema#string

P304

39-47

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/HMG/DDI004

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Raymund A. C. Roos

P577

2004-11-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8194272

http://www.w3.org/2001/XMLSchema#string

P698

15525658

http://www.w3.org/2001/XMLSchema#string

P921

Huntington disease